Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP047: Early fibrostenosis in Crohn’s Disease is associated with multiple susceptibility loci on Immunochip analysis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Holvoet T.
Genetic factors, Fibrosis, Genetics
Files: 1
DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 7
Year: 2016
Source: ECCO'16 DOP
Authors: Reinisch W.
anti-TNF agents, Crohn's Disease
Files: 1
DOP048: PROFILE trial: Predicting outcomes for Crohn’s Disease using a molecular biomarker
Year: 2017
Source: ECCO'17 Barcelona
Authors: Noor N.
Natural history, Genetics, T cell
Files: 1
DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with Inflammatory Bowel Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Yarur Andres
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant Ulcerative Colitis patients: A prospective study
Year: 2018
Source: ECCO'18 Vienna
Authors: Tarabar Dino
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP049: Efficacy and safety of golimumab induction for moderate to severe ulcerative colitis in the United Kingdom: Results from the GO-COLITIS study
Year: 2016
Source: ECCO'16 DOP
Authors: Probert C.
anti-TNF agents, Ulcerative Colitis
Files: 1
DOP049: Inflammatory dyskinesis: defects of NF-κ B dynamic behaviour as a new potential biomarker for personalized medicine in Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Sellge G.
Immunology, Macrophage, T cell
Files: 1
DOP04: Matching between donors and patients in fecal microbiota transplantation is important for long-term maintenance on Ulcerative Colitis
Year: 2020
Source: ECCO'20 Vienna
Authors: Dai Ishikawa
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP050: Influence of disease location on vedolizumab efficacy in Inflammatory Bowel Disease: A real-life multicentre experience
Year: 2018
Source: ECCO'18 Vienna
Authors: Pestour Sandie
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: van Haaften W.
Crohn's disease, Inflixmab, Fibroblast, Fibrosis, Mesenchymal cell
Files: 1
DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s Disease but not Ulcerative Colitis: A multi-centre consortium analysis
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP052: Molecular response to Ustekinumab in moderate-to-severe Crohn’s Disease by serum protein and biopsy gene expression analysis: Results from Ustekinumab phase 3 studies
Year: 2017
Source: ECCO'17 Barcelona
Authors: Li K.
Crohn's disease, Ustekinumab, Immunology
Files: 1
DOP052: Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomized, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate to severe ulcerative colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Sandborn W.
Ulcerative Colitis, ozanimod
Files: 1
DOP052: Vedolizumab versus ustekinumab for Crohn's Disease: Comparative effectiveness in a real-life observational cohort study (ICC Case Series)
Year: 2018
Source: ECCO'18 Vienna
Authors: Biemans Vince
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate to severe Crohn’s disease: Results of two Phase 2b randomized placebo-controlled trials
Year: 2016
Source: ECCO'16 DOP
Authors: Panés J.
Crohn's Disease, tofacitinib
Files: 1
DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: A multicentre consortium propensity score–matched analysis
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn’s Disease: An exploratory analysis of the GEMINI 2 and GEMINI 3 studies
Year: 2018
Source: ECCO'18 Vienna
Authors: van Assche Gert
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP055: Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active Ulcerative Colitis patients
Year: 2018
Source: ECCO'18 Vienna
Authors: Atreya Raja
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP055: Results of the Fifth Scientific Workshop of the ECCO (II): Clinical aspects of perianal fistulising Crohn’s Disease - The unmet needs
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gecse K.
Last Modified: Friday, 21 May 2021, 12:32 PM by Admin User
MDT, Perianal disease, Perianal fistulae, Abscess
Files: 1
DOP056: Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn’s Disease who had lost response to anti-TNF#CHR:alpha_LOWER# agents : A multicentre, open-label, Phase 1/2 study
Year: 2018
Source: ECCO'18 Vienna
Authors: Matsuoka Katsuyoshi
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1